Company Overview

Grifols, S.A. is a global healthcare company specializing in plasma-derived medicines, transfusion medicine, and diagnostic solutions. The company operates primarily within the biopharmaceutical and medical diagnostics industries, with its core business focused on the collection of human plasma and the development, manufacturing, and distribution of plasma-derived therapies used to treat rare, chronic, and life-threatening conditions. Grifols serves hospitals, pharmacies, blood banks, and healthcare providers, with significant exposure to immunology, hematology, pulmonology, and critical care.

Founded in 1940 in Spain, Grifols has evolved from a local clinical laboratory into one of the world’s largest vertically integrated plasma companies. A defining strategic advantage is its control over the full plasma value chain, from donor collection through manufacturing and global distribution. This vertically integrated model, combined with a large network of plasma collection centers and long-standing regulatory expertise, has positioned Grifols as a leading global supplier of plasma-derived therapies.

Business Operations

Grifols organizes its activities into several operating segments, led by Biopharma, which generates the majority of revenue through plasma-derived medicines such as immunoglobulins, albumin, alpha-1 antitrypsin, and coagulation factors. The Diagnostic segment focuses on transfusion medicine, clinical diagnostics, and blood screening systems, while Bio Supplies provides plasma and related biological materials to third parties for research and manufacturing use. An Other segment includes hospital products, contract manufacturing, and ancillary services.

The company operates an extensive international infrastructure, including plasma collection centers, fractionation plants, and R&D facilities. Grifols controls proprietary plasma fractionation technologies and manufacturing assets, particularly in the United States and Europe, which are critical to regulatory compliance and product quality. Major subsidiaries include Grifols Therapeutics, Grifols Diagnostic Solutions, Grifols USA, and Biotest, the latter acquired as a controlling stake to strengthen Grifols’ immunology portfolio and European manufacturing capacity.

Strategic Position & Investments

Grifols’ strategy centers on expanding plasma supply, increasing capacity utilization, and reinforcing its leadership in immunoglobulin therapies, which represent the fastest-growing segment of plasma-derived medicines. Key growth initiatives include the expansion of plasma collection centers, particularly in the United States, and investments in manufacturing efficiency and automation to support long-term demand growth.

A major strategic investment was the acquisition of Biotest, which broadened Grifols’ product portfolio and enhanced its footprint in Europe. The company has also invested in diagnostic innovation and digital transfusion technologies while prioritizing balance sheet stabilization following a period of elevated leverage. Emerging focus areas include next-generation plasma therapies, improved donor management technologies, and selective R&D partnerships aligned with rare disease treatment.

Geographic Footprint

Grifols is headquartered in Barcelona, Spain, and maintains a significant operational presence across North America, Europe, Latin America, and parts of Asia-Pacific. The United States represents the company’s most important market, accounting for the majority of plasma collection activities and a substantial portion of revenue.

Manufacturing and R&D facilities are strategically located in Spain, Germany, United States, and Canada, supporting global distribution. Grifols products are sold in more than 100 countries, and the company maintains international influence through long-term supply agreements, regulatory approvals across multiple jurisdictions, and investments that support localized healthcare infrastructure.

Leadership & Governance

Grifols remains influenced by its founding family while operating under a professional management structure and publicly listed governance standards. Leadership emphasizes long-term investment in critical healthcare infrastructure, scientific innovation, and vertical integration to ensure supply security in plasma-derived medicines.

Key executives include:

• Thomas Glanzmann – Executive Chairman
• Víctor Grífols Deu – Co-Chief Executive Officer
• Raimon Grifols Roura – Co-Chief Executive Officer
• Nacho Abia – Chief Financial Officer
• Antonio Martínez – Chief Operating Officer

The leadership team’s strategic vision focuses on reinforcing Grifols’ global leadership in plasma therapies while maintaining regulatory rigor, operational resilience, and sustainable growth.